Navigation Links
Amsterdam Molecular Therapeutics Reports Full Year Results 2009
Date:2/24/2010

AMSTERDAM, February 24, 2010 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today reported its results for the year to December 31, 2009.

    Highlights
    - Glybera(R) Marketing Authorisation Application submitted to
      European Medicines Agency (EMA, formerly known as EMEA);
    - EMA commenced formal review of Glybera(R) dossier on January
      20, 2010;
    - EMA grants orphan drug designation for AMT's Acute
      Intermittent Porphyria ("AIP") program;
    - EMA grants orphan drug designation for AMT's Duchenne
      Muscular Dystrophy ("DMD") program;
    - SenterNovem awards EUR 4 million investment credit for the
      development of AMT's DMD program;
    - Raised EUR 5 million convertible loan notes, which convert
      into ordinary shares at EUR 3.91 per share;
    - New management team.

Jorn Aldag, Chief Executive Officer of AMT, commented: "In 2009 we announced a rebalancing of our strategy, focused on our lead product Glybera(R), a proprietary product for lipoprotein lipase deficiency (LPLD), together with the ongoing development of four earlier stage progams targeting:
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
2. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
3. Amsterdam Molecular Therapeutics to Appoint Philippe van Holle (Celgene) to Supervisory Board
4. Amsterdam Molecular Therapeutics Reports Full Year Results 2007
5. Amsterdam Molecular Therapeutics to Appoint Alexander Ribbink to Supervisory Board
6. Amsterdam Molecular Therapeutics to Appoint George Morstyn to Supervisory Board
7. Amsterdam Molecular Therapeutics Part of Next Biotech Index
8. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
9. Amsterdam Molecular Therapeutics Reports Full Year Results 2008
10. Amsterdam Molecular Therapeutics Reports Half Year Results 2009
11. The University of Amsterdam Joins the MetaMiner Metabolic Diseases Project
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 16, 2014 The ... since 2013, which is why IBISWorld updated its original ... continues to benefit from an intensified focus on environmental ... for new emission standards for power plants and a ... According to IBISWorld Industry Analyst Sarah Kahn, “a range ...
(Date:12/17/2014)... Washington, USA (PRWEB) December 16, 2014 ... Baum, manager at Philipps- Universität Marburg’s Department of ... and photonics, in the newly released SPIE ... “And never be too shy to ask questions.” ... (science, technology, engineering, and mathematics) occupations ranging from ...
(Date:12/17/2014)... N.J. (PRWEB) December 17, 2014 ... (Euronext: IPN; ADR: IPSEY), today announced ... (referred to as Somatuline®) was approved by the ... treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult ... advanced or metastatic disease to improve progression-free survival ...
(Date:12/17/2014)... This report is a professional and ... an overview analysis, the report introduces quartz tubing ... industry overview, policy analysis, and news analysis, etc. ... witnessed rapid development with key manufacturers increasing their ... mentions quartz tubing upstream raw materials and equipment, ...
Breaking Biology Technology:Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 2Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 3Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 2Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 82020 Quartz Tubing Market: Global Development & Forecasts Analysis Now at DeepResearchReports.com 2
... Systems , a leading Microsoft IT consulting firm ... 2010 and FAST implementation for Array BioPharma, a biopharmaceutical ... targeted small molecule drugs to treat patients afflicted with ... year, Array conducted a proof of concept (POC) with ...
... Texas, Nov. 5, 2010 Lexicon Pharmaceuticals, Inc. ... focused on discovering breakthrough treatments for human disease, today ... reported financial results for the three and nine months ... proof-of-concept for two new mechanisms of action in irritable ...
... Project on Emerging Nanotechnologies (PEN) at the Woodrow ... of voluntary options available for the oversight of ... Initiatives, Regulation, and Nanotechnology Oversight: Charting a Path, ... for Environmental Policy at American University, provides a ...
Cached Biology Technology:Catapult Systems Awarded SharePoint 2010 and FAST Intranet Project 2Catapult Systems Awarded SharePoint 2010 and FAST Intranet Project 3Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2010 Third Quarter Financial Results 2Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2010 Third Quarter Financial Results 3Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2010 Third Quarter Financial Results 4Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2010 Third Quarter Financial Results 5Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2010 Third Quarter Financial Results 6Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2010 Third Quarter Financial Results 7
(Date:12/10/2014)... -- You,ve been here before: you desperately need to sign ... site key or the answer to your secret question. What,s ... Today, Hoyos Labs , a digital infrastructure ... put an end to the frustration that comes with usernames, ... leverages a user,s smartphone to acquire his or her biometrics ...
(Date:12/10/2014)... Dec. 9, 2014 CIE San Diego has ... provides the connective tissue that enhances care coordination among ... easily share client-level information; earned a second $1 million ... organizations serving seniors aging in community and; will be ... December 11 th 4-6p. CIE San ...
(Date:12/5/2014)... 2014 Increased emphasis on product quality, ... testing and inspection technologies. The convergence of industries ... range of innovative test solutions. This trend is ... which is generally more inclined towards communication, media ... strategies of test equipment vendors will cater to ...
Breaking Biology News(10 mins):The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4
... created a bio patch to regenerate missing or damaged ... delivers bone-producing instructions directly into cells. The bone-regeneration ... containing the genes needed for producing bone. In experiments, ... to cover skull wounds in test animals. It also ...
... to Canada,s fisheries legislation "have eviscerated" the ability ... fish species, scientists at the University of Calgary ... The changes were "politically motivated," unsupported by ... and are inconsistent with ecosystem-based management, fisheries biologists ...
... Catherine Pickering, said the Griffith study looked at the ... dispersed through horse manure. The findings have been published ... "We reviewed 15 studies on seed germination from ... three from Australia and one study each from Africa ...
Cached Biology News:A bio patch that can regrow bone 2A bio patch that can regrow bone 3Changes to fisheries legislation have removed habitat protection for most fish species in Canada 2Saddling up against the threat to our National Parks 2
... of siRNA while maintaining high cell viability ... samples simultaneously , Fast: less ... post-electroporation incubation , Highly reproducible ... for use with the Bio-Rad Gene Pulser ...
Mouse CXCR3 Allophycocyanin MAb (Clone 220803)...
Request Info...
Recombinant Rat Leptin, Ultra Pure...
Biology Products: